Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

of docetaxel plus placebo.

In April, sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP® (aflibercept) in combination with the FOLFIRI chemotherapy regimen (folinic acid, 5-fluorouracil, and irinotecan) versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer. The full study results will be presented at an upcoming medical meeting.

In addition to VITAL and VELOUR, the program includes one Phase III trial and one Phase II trial, all of which are fully enrolled. An interim analysis of the VENICE Phase III study evaluating aflibercept as a first-line treatment for hormone-refractory metastatic prostate cancer in combination with docetaxel and prednisone is expected to be conducted by an Independent Data Monitoring Committee in mid 2011. Final results of VENICE are anticipated in 2012. Final results of the AFFIRM Phase II study, evaluating aflibercept as a first-line treatment in metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), are expected during the second half of 2011.

A pediatric hexavalent vaccine (DTP-HepB-Polio-Hib) entered Phase III.

Two compounds entered Phase II

  • SAR110894D, a selective oral H3 receptor antagonist for Alzheimer's disease
  • SAR231893/ REGN668 (partnership with Regeneron), a monoclonal antibody anti IL4-R developed for asthma

  • Two compounds entered Phase I

  • SAR156597, a potential first-in-class bi-specific IL4/IL13 antibody for the treatment of patients with idiopathic pulmonary fibrosis
  • SAR307746/REGN910 (partnership with Regeneron), is a fully human IgG1 monoclonal antibody directed against Ang2 entered Phase I in oncology

  • SSR125543, a CRF1 antagonist, did not meet its endpoint in Phase II trial in patients with de
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
    (Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
    (Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
    Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
    (Date:8/30/2014)... August 30, 2014 In today’s world, ... increasingly difficult to get. Snoring and sleep apnea (a ... breathing stops) robs people and their bed partners of ... Up to 45% of the population snores and 20 ... apnea. Of these, only 10% have been diagnosed and ...
    (Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
    (Date:8/30/2014)... FL (PRWEB) August 30, 2014 McLeod's ... full service auto repair shop with strong ties to the ... Family is happy to announce they have been chosen by ... one pick for auto repair. , Tim McLeod’s father, ... Auto Service sixty years ago. Although his son, Tim runs ...
    (Date:8/30/2014)... 2014 The SI Joint Evaluation and ... six muscle energy techniques. Michael P. Reiman PT, DPT, ... examination techniques for the SI Joint. This ... live course presentation with North American Seminars. ... Applying a differential diagnosis approach to a thorough examination ...
    (Date:8/30/2014)... 30, 2014 What challenges exist in ... the latest trends, concerns, and considerations? Sports Conflict ... Pendleton recently spoke with Woody Wommack, Southeast Football Recruiting ... issues in football recruiting. Notably, Wommack spoke on ... changes that he thinks are coming as a result ...
    Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
    ... Response Systems,announced today two new contract awards, worth ... surge capacity for hospitals and,public health systems in ... Suffolk County, NY., The first contract, for ... the Idaho Central District Health Department. This,contract includes ...
    ... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
    ... Omnicell, Inc.,(Nasdaq: OMCL ), a leading ... announced that it has entered into a definitive ... cash transaction valued at,approximately $26 million, subject to ... that brings quality healthcare to the,bedside through a ...
    ... rate of decline in lung function in children and adolescents ... Researchers found that patients with cystic fibrosis (CF) who took ... loss of lung function compared to those who did not ... two to seven years. , It is fairly evident ...
    ... Assay Developed Specifically for Resource-Limited ... Settings Joins Global Procurement Consortium, UPPSALA, Sweden, November ... today announced an agreement with the Clinton,Foundation HIV/AIDS Initiative ... immediately available to members of CHAI,s,Procurement Consortium at a ...
    ... Nov. 29 AstraZeneca (NYSE:,AZN) today announced that the ... an additional six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) ... to pediatric exclusivity being,granted by the FDA, the patent ... is currently approved in the US for the for ...
    Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
    ... Laserex Super Q is an Nd: YAG ... and reliable means for performing posterior capsulotomy, ... Q delivers benchmark performance in an elegant, ... Laserex Super Q produces a 1064 nm ...
    ... Ultrasonix ES500 system is an innovative, ... that provides excellent clinical performance. The ... processing of the ES500 system deliver ... and every system offers a full ...
    Protects the eye during or after surgery or trauma. Smooth edges need no protective cover. Connected with elastic at nose. Adjustable hook/loop material for a comfortable fit....
    Protects the eye during or after surgery or trauma...
    Medicine Products: